Comparative Pharmacology
Head-to-head clinical analysis: ANAFRANIL versus TRIMIPRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAFRANIL versus TRIMIPRAMINE MALEATE.
ANAFRANIL vs TRIMIPRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
Inhibits reuptake of norepinephrine and serotonin, with moderate anticholinergic, sedative, and antihistaminergic effects.
Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.
25-150 mg orally once daily at bedtime, starting at 25 mg and titrating up by 25 mg every 3-4 days.
None Documented
None Documented
Terminal elimination half-life of clomipramine is approximately 21-26 hours; its active metabolite, desmethylclomipramine, has a half-life of approximately 36-42 hours. Steady-state is achieved within 7-14 days.
Terminal elimination half-life: 22–32 hours (mean 24 hours); in elderly or hepatic impairment, may extend to 40–50 hours requiring dose adjustment.
Renal (primarily as conjugated metabolites, ~60-70% over 72 hours); fecal (biliary excretion of ~10-20%); <2% excreted unchanged in urine.
Renal: ~70% as metabolites (unchanged <5%); fecal: ~30% via biliary excretion.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant